Texas Tech University Health Sciences Center-El Paso

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Childhood cancers2 trials
• Coronary artery disease1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial
• Sarcoma1 trial
• Stroke1 trial
• Thyroid cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Completed1 trial
• Recruiting1 trial
• Suspended1 trial

Lead sponsor

• National Cancer Institute (NCI)2 trials
• Children's Oncology Group1 trial
• Janssen Research & Development, LLC1 trial
• NRG Oncology1 trial
• Santiago Ortega Gutierrez1 trial

Running trials

• Recruiting

  Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe

  NCT06825897· Santiago Ortega Gutierrez· Source

  Contact: Israel Alba

• Active, not recruiting

  Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source